359 related articles for article (PubMed ID: 27936028)
1. Cost Effectiveness of Screening Colonoscopy Depends on Adequate Bowel Preparation Rates - A Modeling Study.
Kingsley J; Karanth S; Revere FL; Agrawal D
PLoS One; 2016; 11(12):e0167452. PubMed ID: 27936028
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies.
Sharaf RN; Ladabaum U
Am J Gastroenterol; 2013 Jan; 108(1):120-32. PubMed ID: 23247579
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of screening for colorectal cancer in the general population.
Frazier AL; Colditz GA; Fuchs CS; Kuntz KM
JAMA; 2000 Oct; 284(15):1954-61. PubMed ID: 11035892
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness and projected national impact of colorectal cancer screening in France.
Hassan C; Benamouzig R; Spada C; Ponchon T; Zullo A; Saurin JC; Costamagna G
Endoscopy; 2011 Sep; 43(9):780-93. PubMed ID: 21623557
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
Ladabaum U; Mannalithara A
Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries.
Wu GH; Wang YM; Yen AM; Wong JM; Lai HC; Warwick J; Chen TH
BMC Cancer; 2006 May; 6():136. PubMed ID: 16723013
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of colorectal cancer screening programmes using sigmoidoscopy and immunochemical faecal occult blood test.
Senore C; Hassan C; Regge D; Pagano E; Iussich G; Correale L; Segnan N
J Med Screen; 2019 Jun; 26(2):76-83. PubMed ID: 30180780
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of colonoscopy in screening for colorectal cancer.
Sonnenberg A; Delcò F; Inadomi JM
Ann Intern Med; 2000 Oct; 133(8):573-84. PubMed ID: 11033584
[TBL] [Abstract][Full Text] [Related]
9. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of screening strategies for colorectal cancer.
Barzi A; Lenz HJ; Quinn DI; Sadeghi S
Cancer; 2017 May; 123(9):1516-1527. PubMed ID: 28117881
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia.
Lew JB; St John DJB; Macrae FA; Emery JD; Ee HC; Jenkins MA; He E; Grogan P; Caruana M; Sarfati D; Greuter MJE; Coupé VMH; Canfell K
Int J Cancer; 2018 Jul; 143(2):269-282. PubMed ID: 29441568
[TBL] [Abstract][Full Text] [Related]
12. Should colorectal cancer screening be considered in elderly persons without previous screening? A cost-effectiveness analysis.
van Hees F; Habbema JD; Meester RG; Lansdorp-Vogelaar I; van Ballegooijen M; Zauber AG
Ann Intern Med; 2014 Jun; 160(11):750-9. PubMed ID: 24887616
[TBL] [Abstract][Full Text] [Related]
13. Optimal use of colonoscopy and fecal immunochemical test for population-based colorectal cancer screening: a cost-effectiveness analysis using Japanese data.
Sekiguchi M; Igarashi A; Matsuda T; Matsumoto M; Sakamoto T; Nakajima T; Kakugawa Y; Yamamoto S; Saito H; Saito Y
Jpn J Clin Oncol; 2016 Feb; 46(2):116-25. PubMed ID: 26685321
[TBL] [Abstract][Full Text] [Related]
14. Screening based on risk for colorectal cancer is the most cost-effective approach.
Dan YY; Chuah BY; Koh DC; Yeoh KG
Clin Gastroenterol Hepatol; 2012 Mar; 10(3):266-71.e1-6. PubMed ID: 22100624
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
Phisalprapa P; Supakankunti S; Chaiyakunapruk N
J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
[No Abstract] [Full Text] [Related]
16. Fecal occult blood testing when colonoscopy capacity is limited.
Wilschut JA; Habbema JD; van Leerdam ME; Hol L; Lansdorp-Vogelaar I; Kuipers EJ; van Ballegooijen M
J Natl Cancer Inst; 2011 Dec; 103(23):1741-51. PubMed ID: 22076285
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Multitarget Stool DNA Testing vs Colonoscopy or Fecal Immunochemical Testing for Colorectal Cancer Screening in Alaska Native People.
Redwood DG; Dinh TA; Kisiel JB; Borah BJ; Moriarty JP; Provost EM; Sacco FD; Tiesinga JJ; Ahlquist DA
Mayo Clin Proc; 2021 May; 96(5):1203-1217. PubMed ID: 33840520
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of colorectal cancer screening: comparison of community-based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy.
O'Leary BA; Olynyk JK; Neville AM; Platell CF
J Gastroenterol Hepatol; 2004 Jan; 19(1):38-47. PubMed ID: 14675241
[TBL] [Abstract][Full Text] [Related]
19. Primary prevention of colorectal cancer with low-dose aspirin in combination with endoscopy: a cost-effectiveness analysis.
Hassan C; Rex DK; Cooper GS; Zullo A; Launois R; Benamouzig R
Gut; 2012 Aug; 61(8):1172-9. PubMed ID: 21997545
[TBL] [Abstract][Full Text] [Related]
20. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]